Share chart Nanobiotix S.A.
Extended chart
Simple chart
About
Nanobiotix S.A., биотехнология на клинической стадии, специализируется на разработке продуктов-кандидатов для лечения рака. Компания разрабатывает продукты NanoXray, чтобы помочь пациентам, получающим лучевую терапию, усилить эффект лучевой терапии внутри опухолевых клеток без увеличения дозы для окружающих здоровых тканей. more details| EBITDA | -0.0448 |
|---|---|
| EV/EBITDA | -0.2107 |
| IPO date | 2020-12-11 |
| ISIN | US63009J1079 |
| Industry | Biotechnology |
| P/BV | 4.65 |
| P/S | 6550.52 |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | eur |
| Выручка | 6.8E-5 |
| Сайт | https://www.nanobiotix.com |
| Цена ао | 4.4 |
| Число акций ао | 0.03693 млрд |
| Change price per day: | +1.36% (2.94) |
|---|---|
| Change price per week: | -3.87% (3.1) |
| Change price per month: | -11.04% (3.35) |
| Change price per 3 month: | -44.09% (5.33) |
| Change price per half year: | -44.76% (5.395) |
| Change price per year: | -59.07% (7.28) |
| Change price per 3 year: | -64.82% (8.47) |
| Change price per 5 year: | 0% (2.98) |
| Change price per 10 year: | 0% (2.98) |
| Change price per year to date: | 0% (2.98) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Qube Research & Technologies Ltd | 619 | 0 |
| Perceptive Advisors LLC | 555 | 1.18 |
| Tower Research Capital LLC (TRC) | 450 | 0 |
| Bank of America Corporation | 262 | 0 |
| Blackrock Inc. | 253 | 0.54 |
| Royal Bank of Canada | 34 | 0 |
| Johnson & Johnson | 6 | 11.93 |
| Baillie Gifford and Company | 3 | 6.09 |
| UBS Group AG | 3 | 0.01 |
| Gamma Investing LLC | 1 | 0 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Laurent Levy Ph.D. | Co-Founder, President of the Executive Board & CEO | 687.98k | 1973 (52 years) |
| Ms. Anne-Juliette Hermant M.A. | Chief People Officer & Member of Executive Board | 335.51k | 1974 (51 year) |
| Mr. Earl J. Bergey Ph.d. | Co-Founder | N/A | 1955 (70 years) |
| Mr. Bart Van Rhijn | Chief Financial & Business Officer and Member of Executive Board | 610.31k | 1973 (52 years) |
| Mr. Brandon Owens | VP of Strategic Marketing & Corporate Communication | N/A | |
| Ms. Margaret Galluzzi | VP & Global Head of Clinical Operations | N/A | |
| Mr. Ventzislav Vassilev M.D. | VP & Global Head of Safety Vigilance | N/A | |
| Mr. Craig West CFA | Senior Vice President of Investor Relations | N/A | |
| Dr. Louis Kayitalire M.D. | Chief Medical Officer | 1958 (67 years) | |
| Dr. Leonard A. Farber M.D. | Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board |
Address: France, Paris, 60 rue de Wattignies - open in Google maps, open in Yandex maps
Website: https://www.nanobiotix.com
Website: https://www.nanobiotix.com
